PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33655698-11	2021	Furthermore, in patients with NSCLC who underwent ICI treatment, patients with TP53/KMT2C co-mutations had significantly longer PFS and greater durable clinical benefit (HR: 0.48, 95% CI: 0.24-0.94, p = 0.033).	2-I-ICI-H	50-53	lysine methyltransferase 2C	Homo sapiens	84-89	
33655698-14	2021	TP53/KMT2C co-mutation might serve as a predictive biomarker for ICI responses in NSCLC.	2-I-ICI-H	65-68	lysine methyltransferase 2C	Homo sapiens	5-10